The Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...
SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The Federal Trade Commission said the companies made $7.3 billion over five years from the inflated drug prices This article ...
Valuation metrics highlight Ford’s appeal to bargain hunters, with a P/E of 11.07 and a forward P/E of just 5.74. For income seekers, Ford’s 6.18% dividend yield is particularly enticing. Technically, ...
Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
From 2017 to 2022, the companies -- UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts -- ...
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on ...